Ali Behbahani, a director of CRISPR Therapeutics AG (NASDAQ:CRSP), filed a statement of changes in beneficial ownership on September 21, 2026, reporting the receipt of common shares through a pro rata distribution by NEA Partners 15, L.P. on August 6, 2025.

Key Highlights

  • Reporting person: Ali Behbahani, identified as a Director of CRISPR Therapeutics AG
  • Transaction type: Transaction code "J" - a pro rata distribution for no consideration ($0.00 per share) by NEA Partners 15, L.P. to its limited partners
  • Direct holdings after distribution: Behbahani directly holds 316 common shares following the transaction
  • Indirect holdings: The Ali Behbahani Revocable Trust Dated June 26, 2015 received 15 common shares, bringing indirectly held shares to 29
  • Disclaimer: Behbahani disclaims beneficial ownership of the shares held by the Behbahani Trust in which he has no pecuniary interest, according to the filing

Details of the NEA Partners 15 Distribution to Director Ali Behbahani

According to the filing, NEA Partners 15, L.P. conducted a pro rata distribution of common shares of CRISPR Therapeutics AG to its limited partners on August 6, 2025. The distribution carried no monetary consideration, with both transactions recorded at a price of $0.00 per share. Behbahani, who serves on the board of directors of CRISPR Therapeutics AG, a biopharmaceutical company focused on gene-editing therapies using CRISPR-Cas9 technology, received 60 common shares directly in the distribution, bringing his direct beneficial ownership to 316 common shares.

The filing further discloses that the Ali Behbahani Revocable Trust Dated June 26, 2015 - referred to in the filing as the "Behbahani Trust" - separately received 15 common shares in the same NEA Partners 15 distribution, resulting in a total of 29 common shares held indirectly. The filing states that Behbahani is the trustee of the Behbahani Trust, which is identified as the direct beneficial owner of those securities. Both transactions are reported under transaction code "J" and are classified as acquisitions in Table I of the filing.

What Was Disclosed

The filing reports two related acquisitions of CRISPR Therapeutics AG common shares by director Ali Behbahani through a pro rata distribution from NEA Partners 15, L.P. at no cost, with resulting direct ownership of 316 shares and indirect ownership through a revocable trust of 29 shares.